米非司酮配伍米索前列醇终止13～25周妊娠临床观察

Analysis of mifepristone and misoprostol terminated pregnancy for12-24 weeks

目的探讨口服米非司酮配伍米索前列醇妊娠的安全性及疗效。方法回顾分析终止妊娠的妇女142例。随机分为A组71例口服米非司酮配伍米索前列醇，B组71例接受羊膜腔穿刺引产术。结果A组完全流产率明显高于B纸P〈0．01），A、B两组不全流产相比，有差异（P〈0．01），同时A组所致腹痛较轻，且产程时间缩短、产后出血量少。结论口米非司酮配伍米索前列醇阴道上药用于终止12～24周妊娠，效果优于羊膜腔引产术。

Objective： To study the safety and efficacy by oral administration of mifepristone and misoprostol pregnancy. Methods： To retrospective analyze 142 cases women who terminated pregnancy and were randomly divided into 2 groups. A group included 71 cases of oral mifepristone and misoprostol, B group included 71 cases of amniotic puncture to accept induction technique. Results： The complete abortion rate of A group was significantly higher than B group （P 〈0. 01）, compared the incomplete abortion of A group to B, there is difference （P 〈0.0 1）, abdominal pain caused by group. A the same time, A group has a result of light abdominal pain. Shortened labor time, and less postpartum bleeding. Conclusion： Mifepristone matched Misoprefil was superior to amniotic membrane cavity for terminated 12-24 weeks of pregnancy by using medicine in the vagina